Showing 1 - 20 results of 25 for search 'Lonial, S', query time: 0.04s
Refine Results
-
1
-
2
PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIP... by N. Munshi, A. Spencer, M. S. Raab, A. Masood, M. Martinez-Prieto, J. Chu, S. Iida, S. Lonial, M. A. Dimopoulos
Published 2022-06-01
Article -
3
P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY by P Rodríguez-Otero, J San-Miguel, LD Anderson, Jr, S Lonial, A Truppel-Hartmann, J Sanford, E Rowe, TB Campbell, N Munshi
Published 2022-04-01
Article -
4
-
5
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture by Doan C. Nguyen, Celia Saney, Ian T. Hentenaar, Monica Cabrera-Mora, Violeta Capric, Matthew C. Woodruff, Joel Andrews, Sagar Lonial, Ignacio Sanz, F. Eun-Hyung Lee
Published 2024-02-01
Article -
6
P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL by M. Amatangelo, Y. Cheng, W. Pierceall, N. W. van de Donk, S. Lonial, M. Wang, J. Emerson, K. Hong, P. Maciag, T. Peluso, A. Gandhi, A. Thakurta
Published 2022-06-01
Article -
7
P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LA... by N. W. van de Donk, S. Guo, L. Shi, J. Lord-Bessen, D. Tang, L. Karlin, K. Weisel, K. Ramasamy, P. C. Abad, A. Amin, S. Amin, S. Lonial
Published 2022-06-01
Article -
8
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma by Amatangelo, M, Flynt, E, Stong, N, Ray, P, Van Oekelen, O, Wang, M, Ortiz, M, Maciag, P, Peluso, T, Parekh, S, van de Donk, NWCJ, Lonial, S, Thakurta, A
Published 2024Journal article -
9
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
Published 2023-12-01
Article -
10
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel by Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos
Published 2023-08-01
Article -
11
PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT... by Sagar Lonial, Hang Quach, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Jesus Berdeja, Paul Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia Abad, Juliane Morando, Niels W.C.J. van de Donk
Published 2023-08-01
Article -
12
Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up by A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska
Published 2020-09-01
Article -
13
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma by Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji K. Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar
Published 2023-01-01
Article -
14
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by N. W. C. J van de Donk, R Popat, C Hulin, S Jagannath, A Oriol, P. G Richardson, T Facon, K Weisel, J. T Larsen, M Minnema, A Abdallah, A. Z Badros, S Knop, E. A Stadtmauer, M Chen, T. V Nguyen, A Amin, T Peluso, S Lonial
Published 2022-04-01
Article -
15
P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRM... by A. Nooka, S. Lonial, S. Grosicki, M. Hus, K. Song, T. Facon, N. S. Callander, V. Ribrag, K. Uttervall, H. Quach, V. Vorobyev, C.-K. Min, S. Cheng, L. M. Smith, J. Yu, T. Collingwood, B. Holkova, B. E. Kremer, I. V. Gupta, P. G. Richardson, M. C. Minnema
Published 2022-06-01
Article -
16
P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 T... by Nizar J Bahlis, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z Orlowski, Kihyun Kim, Maria-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Ignacio Casas-Avilés, Alessia Spirli, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Paul Richardson
Published 2023-08-01
Article -
17
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL by A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial
Published 2023-05-01
Article -
18
P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY by Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia
Published 2023-08-01
Article -
19
Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma by Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David Siegel, William Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin Shah, Sharon Shacham, Sagar Lonial
Published 2021-02-01
Article -
20
Venetoclax ex vivo functional profiling predicts improved progression-free survival by Vikas A. Gupta, Shannon M. Matulis, Benjamin G. Barwick, R. Devin Bog, Conrad W. Shebelut, Mala Shanmugam, Paola Neri, Nizar J. Bahlis, Madhav V. Dhodapkar, Leonard T. Heffner, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Jonathan L. Kaufman, David L. Jaye, Ajay K. Nooka, Lawrence H. Boise
Published 2022-08-01
Article